CAREPath: New AI Framework Improves Drug Repurposing by Balancing Mechanistic Reasoning and Context
Researchers have developed CAREPath, a computational framework that uses biomedical knowledge graphs and large language models to identify new uses for existing drugs. The system balances two search strategies—one focused on short, mechanistically specific drug-gene-disease paths and another that captures broader biological context—outperforming 18 baseline methods across five biomedical knowledge graphs. More accurate and interpretable drug repurposing tools could accelerate the identification of new treatments while reducing the cost and time of drug development.
CAREPath is a new knowledge graph and language model (KG-LLM) framework designed to improve computational drug repurposing by reasoning about how drugs interact with diseases through gene-mediated biological mechanisms. The system addresses a known limitation in graph traversal: longer paths through biomedical knowledge graphs tend to pass through highly connected 'hub' genes, generating noise rather than meaningful mechanistic insight. To counter this, CAREPath employs a depth-first search (DFS)-like module that restricts traversal to short disease-gene-drug paths and encodes them as semantic embeddings using a biomedical language model. A complementary breadth-first search (BFS)-like module captures one-hop gene neighborhoods and enriches them by drawing on pharmacologically related drugs and gene-signature-similar diseases. Tested across five biomedical knowledge graphs against 18 baseline methods, CAREPath achieved the best overall AUPRC—a measure of predictive accuracy—improving performance by up to 3.8%. The framework also demonstrated improved robustness when biological evidence is sparse and showed stronger alignment with Gene Ontology functional annotations. Case studies involving recently FDA-approved drug indications suggest the approach has practical clinical relevance, and the source code has been made publicly available.
What's missing
The study does not report external prospective validation—i.e., whether CAREPath's novel repurposing predictions have been experimentally or clinically confirmed beyond alignment with known FDA approvals. The generalizability of the framework to knowledge graphs outside the five tested, or to disease areas underrepresented in current biomedical KGs, is not addressed.
What different sources said
- bioRxivCenter
CAREPath: Semantic Context-Aware Reasoning Paths with Mechanism-Augmented Embeddings for Drug Repurposing
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.